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Key Clinical Message
Hemoglobin S is known to protect against uncomplicated Plasmodium falciparum malaria. However, there is paucity of the literature regarding interaction
of HbS and other malaria species. Usually, P. vivax malaria is a relapsing condition, and without radical cure with primaquine, recurrence may be observed
even with hemoglobin S.
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A 26-year-old man and known patient of sickle cell
disease presented with high-grade fever, chills, and bone
pains since few days in 2016. Physical findings included
marked pallor, hepatosplenomegaly, and short right middle finger possibly representing childhood dactylitis
(Fig. 1 panel A). His transfusion was initiated at the age
of one and a half years and since then received occasional red cells support. He was treated with hydroxyurea for past few years. Past history was significant for
recurrent vivax malaria in 2010 and 2011 and was treated with artemether. He did not receive any primaquine
therapy for radical cure. Current complete blood counts
showed hemoglobin 5.4 g/dL, Hct 16.1, MCV 62.2 fl,
MCH 20.8 pG, white cells 16.5 9 109/L, neutrophils
47%, lymphocytes 41%, monocytes 10%, eosinophil 2%,
and platelets 203 9 109/L. Serum ferritin was 2848.5 ng/
mL, serum calcium 9.4 mg/dL, serum phosphate
3.09 mg/dL, alanine transaminase 60 U/L, and creatinine
0.5 mg/dL. Peripheral blood film displayed (Fig. 1 panel
B) hypochromic microcytic red blood cells, anisocytosis,
poikilocytosis, occasional sickle cells, and features of
hyposplenism (Howell–Jolly bodies, nucleated red blood

cells, and target cells). The smear also showed various
stages of Plasmodium vivax (Fig. 1 panel C: gametocyte;
single arrow and D: schizont; single arrow and trophozoite; double arrows). High-performance liquid chromatography showed Hb S: 90.5%, Hb F: 4.4%, and Hb
A2: 5.1% consistent with sickle/b-thalassemia. DEXA
scan showed normal T and Z score. He was nonreactive
to anti-HIV, HBsAg, and anti-HCV antibodies. He was
treated successfully with artemisinin, and primaquine
was administered to prevent recurrence. The patient was
afebrile at his last follow-up in 2017 with a negative ICT
malaria test.
Hemoglobin S (HbS) reportedly confers protection
against uncomplicated P. falciparum malaria in sickle cell
trait [1]. Although exact defensive mechanisms are not
clear, a number of biochemical and immunological mechanisms have been proposed [2]. Spleen also plays a
mechanical role in phagocytosis of parasitized red blood
cells [3]. In contrast to P. falciparum malaria, no studies
investigated the protective effect of Hb S against P. vivax
malaria [4]. Latter is by its very nature a relapsing infection unless treated by hypnozoicidal agents [5].
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Figure 1. Panel A shows short right middle finger possibly representing childhood dactylitis. Panel B shows peripheral blood film displaying
hypochromic microcytic red blood cells, anisocytosis, poikilocytosis, occasional sickle cells, and features of hyposplenism (Howell–Jolly bodies,
nucleated red blood cells, and target cells. Panel C shows gametocyte of Plasmodium vivax. Panel D shows schizont (single arrow) and
trophozoite (double arrows) of P. vivax.

We believe that, in our patient, Hb S did not confer
any protective role, and primary reason for recurrent
P. vivax malaria was failure to treat dormant stages or
hypnozoites. Hyposplenism might have contributed to
malaria relapse to some extent. Moreover, given the preference of this parasite for reticulocytes, it does not seem
particularly surprising that this patient may have contracted the condition. More research is needed to understand the interaction between HbS and other malaria
species.

Acknowledgments
None.

Authorship
BM: diagnosed the case and wrote manuscript. AM: took
photographs and wrote part of manuscript.

1188

Conflict of Interest
The authors declare that they have no conflict of interest.
References
1. Allison, A. C. 1954. Protection afforded by sickle-cell trait
against subtertian malareal infection. Br. Med. J. 1:290–294.
2. Eridani, S. 2011. Sickle cell protection from malaria.
Hematol. Rep. 3:e24.
3. Diakite, S. A., P. A. Ndour, V. Brousse, F. Gay, C. Roussel,
S. Biligui, et al. 2016. Stage-dependent fate of Plasmodium
falciparum-infected red blood cells in the spleen and sicklecell trait-related protection against malaria. Malar. J. 15:482.
4. Taylor, S. M., C. M. Parobek, and R. M. Fairhurst. 2012.
Impact of haemoglobinopathies on the clinical
epidemiology of malaria: a systematic review and metaanalysis. Lancet. Infect. Dis 12:457–468.
5. Janney, H. M. 1952. Primaquine; a new drug for the radical
cure of relapsing vivax malaria. J. Med. Assoc. Ga. 41:126.

ª 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

